Business Context and Reporting Period
This Form 6-K filing by Garden Stage Limited covers the month of July 2025. The report details a registered direct offering completed in late July 2025 to raise capital for working capital and general corporate purposes.
Key Financial Metrics
- Offering Proceeds: Approximately $3,700,000 in net proceeds received after deducting estimated offering expenses.
- Shares Issued: 35,553,820 ordinary shares and 2,852,525 pre-funded warrants.
- Purchase Price: $0.11 per share.
- Transaction Costs: 8.0% of gross proceeds paid to the placement agent (Univest Securities, LLC) plus $100,000 reimbursed for legal fees and other expenses.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, profit, cash flow, margins, debt, or liquidity metrics for the period.
Material Changes
The primary material change reported is the increase in equity capital through the July 2025 Registered Direct Offering, which closed on July 25, 2025. This transaction resulted in the issuance of new ordinary shares and pre-funded warrants, diluting existing shareholders but providing immediate liquidity to the company.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds are designated for working capital and general corporate purposes.
- Forward-Looking Statements: The filing includes standard disclaimers that forward-looking statements are based on current beliefs and are subject to inherent uncertainties. Actual results may differ materially.
- Risks: Investors are directed to the risks and uncertainties described in the Company's annual report on Form 20-F for the year ended December 31, 2024.
- Unusual Items: No unusual items or contingencies were disclosed beyond the standard terms of the securities purchase agreement.
Investor Verification Checklist
- Verify the exact gross proceeds amount to calculate the total transaction costs (8% fee + $100,000 reimbursement) against the $3.7 million net figure.
- Review the Form 20-F filed on July 31, 2024, for the company's historical financial condition and risk factors referenced in this filing.
- Confirm the dilution impact of the 35,553,820 new ordinary shares and 2,852,525 pre-funded warrants on existing shareholders.
- Check the status of the Form F-3 Registration Statement (File No. 333-283618) to ensure no subsequent amendments affect the offering terms.